Hope on the Horizon: Advancing Care for Ashkenazi Jewish Wolfram Syndrome
September 2026 Research Updates
Every day, research into the Ashkenazi Jewish subtype of Wolfram syndrome (WFS1) is moving forward, bringing researchers closer to new ways to diagnose, treat, and ultimately prevent the disease.
The Lab Leading Wolfram Research
Much of this progress is taking place at Washington University in St. Louis (WashU Medicine), led by clinician-scientist Fumihiko Urano, MD, PhD. Dr. Urano is one of the world’s leading experts on the condition, and his clinic is recognized as a center of excellence by the National Organization of Rare Diseases.
Dr. Urano’s lab is studying the underlying causes of the disease, with the goal of developing new approaches to treatment and prevention — and, ultimately, to finding a cure.
Dr. Urano’s lab is pioneering the use of gene editing to target the Jewish variant of Wolfram syndrome. While treatment has traditionally focused on managing symptoms as they appear, Dr. Urano is working to address the disease at its source by correcting the affected gene itself.
This innovative method has shown promise in lab studies with mice. Researchers have successfully corrected the genetic defect and helped affected cells function normally again — an important step toward a treatment that could one day address the underlying cause of the disease.
What Comes Next
To build on this progress, Dr. Urano and his team at WashU Medicine are seeking additional funding to advance three potentially transformative projects:
Move Gene-Editing Treatments Into Clinical Trials
The next phase of Dr. Urano’s gene editing method is to confirm the safety and effectiveness of these treatments before they can move into human clinical trials. If successful in humans, this approach could revolutionize care by offering a one-time, permanent treatment that corrects the underlying genetic defect.
Establish a Critically-Needed Genetic Screening Program
Dr. Urano is also working to improve genetic screening programs to detect the WFS1 variant earlier, which could help patients and their doctors monitor the condition and manage symptoms sooner. A screening program could also give researchers valuable data about the progression of the disease, helping inform future treatments.
Advance Drug Development
Dr. Urano’s team is also developing more effective medications for Wolfram syndrome, to improve treatment and management of the disease while gene-editing approaches continue to advance.
Become Part of These Life-Changing Advancements
We invite you to partner with the Isaac & Carol Auerbach Family Foundation by giving to the Wolfram Ashkenazi Variant Effort (WAVE) Fund, which directly supports Dr. Urano’s groundbreaking research on the Ashkenazi Jewish subtype of Wolfram syndrome.
Philanthropy can accelerate the pace of scientific discovery by giving pioneering researchers like Dr. Urano the resources to pursue promising ideas without delay. Foundation-supported research can also generate the early data and results needed to secure major federal grants and other funding sources, allowing promising projects to grow.
Your contribution will directly support these efforts, providing hope and tangible progress for individuals and families in the Jewish community affected by Wolfram syndrome. And these advancements are not limited to the WSF1 community — discoveries made through this research may also benefit people affected by other variants of Wolfram syndrome, too.
Together, we can revolutionize the diagnosis, treatment, and prevention of this disease — and bring researchers closer to a cure.
